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Summary
Malignant gliomas have been associated with a high rate of glycolytic activity which is believed necessary to
sustain cellular function and integrity. Since lonidamine (LND) is believed to reduce tumor glucose utilization
by inhibition of the mitochondrially-bound glycolytic enzyme hexokinase (HK), 31P magnetic resonance spec-
troscopy (MRS) was used to noninvasively follow the effects of LND on both tumor pH and the high-energy
phosphate metabolites; ATP, phosphocreatine (PCr) and inorganic phosphate (Pi) in subcutaneous rat 9L
gliosarcomas. 31P tumor spectra acquired in 5 min intervals pre- and post LND administration of 50 and
100 mg/kg, i.p. revealed an acidotic pH shift of − 0.25 and − 0.45 pH units, respectively within 30 min post
administration. The ATP/Pi ratio of 9L tumors decreased to 40% of control and Pi levels increased to 280% of
control over a 3 hr period. LND exerted no effect on tumor blood flow and mean arterial blood pressure.
Brain and muscle metabolite levels and pH were also unaffected by LND. In vitro measurements of cultured
9L tumor cell intra- and extracellular lactate, pentose phosphate pathway (PPP) and hexokinase (HK) activ-
ities suggest that the mode of action of LND involves inhibition of lactate efflux and intracellular acidification.
The selective reduction of tumor energy metabolites and pH by LND may be exploitable for sensitizing
gliomas to radiation, chemotherapy or hyperthermia.
Abbreviations: pHe – extracellular pH; GC/MS – gas chromatography/mass spectrometry; LND – lonidamine;
HK – hexokinase, pHi – intracellular pH; KRB – Krebs ringer bicarbonate buffer; MABP – mean arterial
blood pressure, PPP – pentose phosphate pathway; PCr – phosphocreatine; 31P MRS – phosphorus-31
magnetic resonance spectroscopy; SIM – selected ion monitoring
Introduction
Malignant gliomas remain refractory to treatment
despite the development of new antineoplastic
strategies. The rapid cellular proliferation and re-
sistance to therapy exhibited by malignant gliomas
is, in part, due to the ability to maintain essential
energy metabolite levels through abnormally high
rates of glucose utilization and aerobic glycolysis [1,
2]. In highly glycolytic tumor cells, glucose is com-
mitted to metabolism by hexokinase (HK)1, which
catalyses the phosphorylation of glucose at the ex-
pense of mitochondrially-produced ATP. A num-
ber of workers have shown that tumor cells exhibit a
marked elevation in HK activity [3] with reduced
sensitivity to product inhibition by glucose 6-phos-
phate [4]. Moreover, subfractionation studies have
shown that HK in neoplastic cells is preferentially
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bound to the outer surface of the mitochondrial
membrane [5, 6] and it has been suggested that mi-
tochondrially-bound HK has preferred accesses to
ATP generated by oxidative phosphorylation [7].
These studies, taken together, may provide the me-
tabolic basis for the high rates of glucose 6-phos-
phate formation and aerobic glycolysis in malignant
tumors.
It has been suggested that the significantly large
differences in cytosolic versus mitochondrial-
bound hexokinase between normal and malignant
tissue offers an intriguing target for selective me-
tabolic manipulation [6]. The rationale of using
LND in the sensitization of neoplastic cells relies on
the supposition that its mechanism of action in-
volves interference with mitochondrially-bound
hexokinase and aerobic glycolysis [8, 9]. The inter-
ference of glycolysis would result in decreased cel-
lular energy status thereby making tumor cells
more susceptible to damage by radiation or hyper-
thermia treatments. Indeed, several studies have
suggested that LND is beneficial in reducing cell
growth and recovery from damage induced by ad-
junctive therapeutic modalities including radiation
[10–12], hyperthermia [13, 14] and chemotherapy
[15, 16]. Other studies have reported other LND-in-
duced effects such as ultrastructural changes in the
plasma membrane [17] and cytoskeleton [18] and in-
tracellular calcium elevation [19]. More recently, us-
ing a perfused human breast cancer cell line, investi-
gators have shown that exposure of tumor cells to
LND inhibits lactate efflux leading to intracellular
acidification [20].
In this study, in vivo 31P NMR spectroscopy was
used to noninvasively monitor the effects of LND
on the energy state and tumor pH in subcutaneous
9L gliosarcomas in the rat. To date, no reports have
been published demonstrating direct evidence that
LND actually impairs in vivo tumor glucose metab-
olism with subsequent impairment of cellular ener-
gy metabolism. We have also performed in vitro
studies to determine whether inhibition of lactate
efflux plays a role in the mediation of LND-induced
impairment of glucose consumption as was previ-
ously reported in breast tumor cells [20]. Our re-
sults demonstrate that LND indeed causes an im-
pairment of tumor energy state and pH homeosta-
sis and that these effects appear to be associated, at
least in part, with disruption of lactate transport.
The loss of high-energy phosphate stores and de-
cline in intracellular pH may provide a selective ap-
proach for sensitizing gliomas to adjunctive ther-
apeutic modalities. Furthermore, 31P NMR spec-
troscopy allows the effects of LND to be monitored
dynamically in vivo and thereby provides a means




Rat 9L tumor cells were grown in MEM containing
10% fetal bovine serum and antibiotics. Cells were
harvested by trypsinization, counted and suspend-
ed in serum-free MEM at 106 cells/0.1 ml. Subcuta-
neous tumors were induced by injection of 0.2 ml
9L tumor cell suspension in the right thigh muscle of
male Fischer-344 rats under isofluorane anesthesia.
Tumors were allowed grow to approximately
2.5 cm3 for these studies.
In vivo 31P NMR spectroscopy
For all in vivo studies, rats were intubated and venti-
lated with a 1 to 1.25% isofluorane/air mixture and
kept at 37° C using a water-jacketed blanket. Isoflu-
orane was used for in vivo studies since we found
that animals anesthetized with sodium pentobarbi-
tal or a ketamine/xlyazine mixture were not able to
tolerate the 100 mg/kg dose of LND. Cannulation of
a femoral vein was accomplished in order to obtain
blood samples necessary for adjusting the ventila-
tion rate to maintain normal blood pH, PO2 and
PCO2 throughout the experimental period. A Radi-
ometer ABL-300 blood gas analyzer was used for
blood analysis. The tumor was positioned adjacent
to the surface coil probe and the entire apparatus
was placed in the bore of the magnet. 31P NMR ex-
periments were accomplished at 121.4 MHz on a
Varian Imaging system equipped with an 18.3 cm
horizontal bore 7 Tesla magnet. 31P NMR spectra
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were acquired using a 1 cm diameter surface coil
which was switchable to the 1H resonance frequency
(300 MHz) for shimming purposes. 31P spectra were
acquired using the following parameters: 4K data
points per FID, spectral width of 8,000 Hz, repeti-
tion time of 2.3 sec, 132 signal averages per spec-
trum (5 min total accumulation time), and a pulse
length of 18 µs. A minimum of three control 31P
spectra were obtained before administration of
LND through an indwelling i.p. cannula. 31P NMR
spectra were apodized with a 35 Hz exponential
line broadening function prior to Fourier transfor-
mation. Spectral baselines were corrected using a
cubic spline method. Quantification of 31P reso-
nance areas was accomplished using a spectral de-
convolution routine provided with the Varian MR
system. Intracellular pH (pHMRS) was calculated
from the chemical shift of Pi relative to PCr.
For the 31P NMR studies, a total of 9 tumor-bear-
ing rats were divided evenly between control (buff-
er only), 50 and 100 mg/kg LND. The buffer used for
dissolving LND consisted of trizma base (12 g) and
glycine (57.6 g) in 500 ml sterile water (final pH =
8.3). LND (22 mg) was dissolved in 1 ml buffer solu-
tion and vortexed until the solution was clear.
Laser Doppler tumor blood flow measurements
In a separate series of experiments, a laser Dop-
pler blood perfusion monitor (Vasamedics Inc.,
Model No. BPM 403) was used to monitor changes
in microvascular blood flow in subcutaneous 9L
gliosarcomas before and following administration
of LND. The laser emits an infrared light at 760–
800 nm which is transmitted into the tissue
through a right angle probe (Model No. P-430)
containing an optical fiber. The probe was placed
on the surface of the tumor following resection of a
small area of skin over the tumor to allow light
penetration. MABP and rectal temperature were
continuously monitored using a Gould ACQ4600
acquisition recording system interfaced to a desk-
top computer. Before administration of LND was
accomplished, a minimum of 10 minutes of stable
blood flow measurements were recorded. Three
rats were injected with buffer alone (1 ml) and 3
rats were injected with buffer containing LND
(100 mg/kg, i.p.).
Determination of intracellular pH in vitro
Measurements of pHi in vitro were accomplished
using the pH-sensitive fluorescence dye BCECF as
previously described [21]. Briefly, cultured 9L glio-
sarcoma cells were trypsinized and dispersed to sin-
gle cells, resuspended in Tris-buffered RPMI 1640
at pH 7.4 and incubated for 3 hr at 37° C. The cells
(107 cells/ml) were then loaded with 5 µg/ml
BCECF-AM in DMSO and incubated for 30 min at
37° C to allow permeation of the dye and subse-
quent deesterification by endogenous esterases.
After loading with BCECF the cells were centri-
fuged and resuspended in Tris-buffered RPMI 1640
pH 7.4 or Mes/Mops buffered media at pH 6.6 at
2 × 105 cells/ml in 1.5 ml micro centrifuge tubes in
the presence or absence of 100 µM LND for up to
120 min. Aliquots were read in a Hitachi F-2000 flu-
orometer using excitation wavelengths of 440 and
500 nm, emission wavelength of 530 nm and slit
width of 10 nm. The fluorescence ratio was then
converted to actual pH values using a calibration
curve obtained from titration of the cell suspension
to known pH values. Control of intracellular pH
was achieved in a high K+ buffer (124 mM) contain-
ing 10 µg/ml of the ionophore nigericin, which
would allow intra- and extracellular pH to be equal-
ized.
Determination of intra- and extracellular lactate
in vitro
Rat 9L gliosarcoma cells were grown to confluence
in 6-well flat bottom sterile tissue culture plates.
The cells were rinsed 3 times with KRB, pH = 7.4,
and exposed for 60 min to KRB containing 100 µM
LND and 5.5 mM (1,6-13C2,6,6-
2H2) glucose for
quantitation of both lactate and PPP activity (de-
scribed below). Following exposure to LND, the
media was collected for analysis of released lactate
and the plates washed 3 times with cold KRB. Plates
were kept on ice while the tumor cells were re-
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Figure 1. In vivo 31P MR spectra of a subcutaneous 9L tumor (A)
pre- and (B) 3 hr post-administration of LND (100 mg/kg, i.p.).
Resonance assignments are as follows: 1, phosphomonoesters
(PME); 2, inorganic phosphate (Pi); 3, phosphocreatine (PCr); 4,
γ-ATP and β-ADP; 5, α-ATP, α-ADP; and 6, β-ATP. Note the
decline in ATP levels and the corresponding increase in Pi fol-
lowing LND administration (Spectrum B) indicating impaired
energy metabolism.
moved using a rubber policeman after addition of
0.6 M perchloric acid to the wells. The cells were
then homogenized manually and sonicated for
30 sec using a Branson sonifier (Model A 250)
equipped with a micro-tip. The homogenates were
neutralized with equivolumes of KHCO3 centri-
fuged at 1000 × g for 10 min and the supernatant col-
lected for analysis of intracellular lactate. Lactate
levels were determined by GC/MS as previously de-
scribed [22]. In brief, samples were lyophilized to
dryness and derivatized with bis(trimethylsilyl)tri-
fluoroacetamide. A Hewlett Packard 5890/5971
GC/MS system was used for analysis of lactate. SIM
was performed on the m/z 219, 220, 221 and 222 ions
which correspond to the loss of a methyl group from
the trimethylsilyl derivative of lactic acid.
Measurements of pentose phosphate pathway
activity
The method for determination of PPP activity was
described in detail elsewhere [22, 23]. This method
relies on the differential labeling of released lactate
following metabolism of (1,6-13C2,6,6-
2H2)glucose.
Metabolism of this isotopically substituted glucose
molecule through glycolysis produces (3-13C)lac-
tate, originating from the C1 position of glucose,
and (3-13C,3,3-2H2)lactate, originating from the C6
position of glucose. In contrast, metabolism of the
labeled glucose through the PPP produces (3-
13C,3,3-2H2)lactate from the C6 position and unla-
beled lactate from the C1 position since the label in
the C1 position is lost as 13CO2 by the action of the
PPP enzyme phosphogluconate dehydrogenase.
These different lactate isotopomers can be easily
resolved and quantitated by GC/MS and the per-
centage of glucose metabolized through the PPP
relative to glycolysis calculated from the amounts
of each of these lactate isotopomers in the extracted
ion chromatogram. Total lactate production was
determined from the sum of the four lactate ion spe-
cies.
Assay of hexokinase activity
Hexokinase was assayed spectrophotometrically as
previously described [24]. Pelleted 9L gliosarcoma
cells were washed and resuspended in 0.25 M su-
crose, and lysed by brief sonication. The lysate was
centrifuged at 1000 × g for 10 minutes; all hexoki-
nase activity remained in the supernatant. The lat-
ter was then centrifuged at 43,500 × g for 20 min-
utes. This supernatant contained 93% of the initial
total activity. The pellet was resuspended in 0.25 M
sucrose, assayed, and found to contain 6% of the
initial total activity (total recovery, 99% of initial
total activity). The particulate enzyme presumably
represents mitochondrially bound hexokinase, re-
ported to occur in many normal tissues as well as
tumors. Both soluble and particulate hexokinase
fractions were preincubated in assay medium minus
substrate ATP, and 68 µM LND for 10 min. After
the preincubation, the reaction was started by addi-
tion of ATP. Control samples contained only the
Tris-glycine buffer used as solvent for LND. The en-
zyme preparations were preincubated with LND
(25 µM up to 1.25 mM), with or without glucose
present during the incubation with LND.
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Figure 2. The effects of LND on the ATP/Pi ratio (A) and tumor
pH (B) versus time in subcutaneous 9L gliomas following a bolus
i.p. injection of 50 (filled squares) and 100 mg/kg (open squares)
LND (n = 3 ± S.E.).
Figure 3. In vivo 31P MR spectra of the brain (A) pre- and (B) 3 hr
post-administration of LND (100 mg/kg, i.p.). Resonance assign-
ments are as described in Figure 1.
Results
In vivo 31P MRS studies
Shown in Figure 1 are representative 31P MRS spec-
tra of a rat subcutaneous 9L tumor (A) before and
(B) 3 hr following i.p. administration of 100 mg/kg
LND. These spectra reveal a dramatic decline in
ATP with a reciprocal increase in Pi levels. Minimal
changes in intensity of the PCr resonance were ob-
served thus it was assumed that this resonance was
derived primarily from the overlying skin as previ-
ously reported [25]. Injecting rats with drug vehicle
alone (glycine buffer) resulted in no detectable
changes in phosphorus metabolites in the 31P spec-
trum (not shown) indicating that LND is respons-
ible for the deleterious effects on tumor energy me-
tabolism. The decrease in ATP and the increase in
Pi were observed almost immediately following
LND administration. As shown in Figure 2A, the
β-ATP/Pi ratio decreased to about 63% and 40% of
control with 50 and 100 mg/ml LND, respectively, in
the first 30 min of the experiments and remained
low throughout the experimental period. Even
more dramatic was the effect of LND on intracellu-
lar pH, as determined from the chemical shift dif-
ference between the Pi and PCr resonances in the
31P spectrum. Shown in Figure 2B, is the time course
of the average intracellular pH of the tumor pre-
and post-administration of 50 and 100 mg/kg LND.
Tumor pH declined approximately 0.45 pH units
within the first 30 min (with 100 mg/kg) and slowly
returned to within 0.15 pH units 3 hr post-LND. Al-
though less pronounced, the lower dose of 50 mg/kg
LND also resulted in a similar pattern of intracellu-
lar acidification.
The deleterious effects of LND appeared to be
most specific to the tumor since no significant
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Table 1. Effects of LND administration (100 mg/kg, body weight,
i.p.) on rat 9L tumor blood flow and mean arterial blood pressure
(MABP)
Time (min) TBF (normalized) MABP (mmHg)
0 100 88.8 ± 4.4
10 99.2 ± 11.1 82.4 ± 8.9
20 96.6 ± 14.7 81.0 ± 5.2
30 100.2 ± 6.4 86.5 ± 10.6
Values for TBF were obtained from laser Doppler measure-
ments and are expressed as percent of control. All values are
expressed as means ± SD (n = 6).
Figure 4. In vivo 31P MR spectra of the hind leg muscle (A) pre-
and (B) 3 hr post-administration of LND (100 mg/kg, i.p.). Reso-
nance assignments are as described in Figure 1.
Figure 5. Fluorescence measurements of pHi versus time from
suspensions of 9L cells under control conditions at pHe 7.4 (s)
and pHe 6.6 (d), and in the presence of 100 µM LND at pHe 7.4
(h) and at pHe 6.6 (j) (n = 3 ± SD).
change in energy metabolism or intracellular pH
was observed in brain (Figure 3) or skeletal muscle
(Figure 4) following administration of 100 mg/kg
LND. In addition, LND (100 mg/kg) had no appre-
ciable effect on tumor blood flow or MABP as
shown in Table 1. Blood pH, PO2, PCO2 and body
temperature also remained within normal param-
eters (not shown).
In vitro studies
The effects of LND on pHi were also studied in sus-
pensions of 9L cells by fluorescence spectroscopy.
Cells incubated with 100 µM LND had a rapid de-
cline in pHi of 0.20 to 0.25 pH units, which was fol-
lowed by a partial recovery over 120 min (Figure 5).
In an acidic environment, i.e. when medium pH was
kept at 6.6, exposure to LND caused a substantially
larger decline in pHi (e.g. 0.35–0.40 pH units) (Fig-
ure 5).
The effects of LND on intra- and extracellular
lactate levels following a 1 hr exposure of 9L cultur-
es to 100 µM LND was evaluated. In these experi-
ments, lactate was quantitated from GC/MS analy-
sis of the media and PCA extracts. LND induced a
pronounced decrease in the extracellular lactate
concentration to 23 ± 11% (± S.D., n = 4) of control
levels while intracellular lactate accumulated more
than 5-fold (526 ± 56%) indicating an inhibition of
lactate transport.
The effects of LND on cellular PPP activity was
also examined. Since the cytotoxic effects of LND
in a variety of tumor cell types have been ascribed
to inhibition of HK bound to the outer surface of
the mitochondrial membrane [9, 26], we have mea-
sured PPP activity in order to determine whether
such inhibition indeed occurs in 9L tumor cells in
situ. The rational behind these measurements was
that HK inhibition by LND would be expected to
result in a net reduction in glucose 6-phosphate for-
mation available for consumption by the PPP. PPP
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activity (defined as the amount of glucose metabo-
lized to lactate through the PPP versus glycolysis) in
9L cultures in the absence and presence of 100 µM
LND was found to be 10.7 ± 0.8% and 11.0 ± 1.4%,
respectively. Exposure of 9L cells to 100 µM LND
caused no detectable change in PPP activity sug-
gesting that LND exerts minimal inhibition of HK.
Discussion
The 31P MRS data clearly demonstrate that LND
(50–100 mg/kg) exerts marked effects on energy
metabolism and intracellular pH in rat subcutane-
ous 9L tumors in vivo. The rapid and pronounced
intracellular acidification of approximately 0.45 pH
units observed with 100 mg/kg LND could not be
attributed to LND-induced changes in physiolog-
ical parameters such as MABP, tumor blood flow or
blood chemistry since these remained within nor-
mal physiological limits. Furthermore, since a simi-
lar LND-induced decrease in pHi was also observed
in cultured 9L cells, the effect of LND on in vivo
tumor energy metabolism is most likely due to a di-
rect action on the tumor rather than an indirect ef-
fect on the host animal.
It is currently hypothesized that a major mecha-
nism of LND action is the inhibition of mitochon-
drially-bound HK and subsequently of aerobic gly-
colysis. Floridi et al. [9] have reported 66% inhib-
ition of mitochondrial HK with 5 µM LND with ve-
ry little effect on cytoplasmic HK. To test whether
this hypothesis is applicable to 9L gliosarcoma cells,
sub-cellular fractionation of 9L cells was accom-
plished. An assay for HK activity in the supernatant
and pellet was then done (Wilson J.E., personal
communication). The protocol we used was similar
to one previously described [9], and the concentra-
tion of LND was well above the levels (2–5 µM) re-
ported by these authors which they reported caused
marked inhibition of the mitochondrially-bound
enzyme. The supernatant obtained from 9L cells
was found to contain 93% of the initial total HK ac-
tivity whereas the pellet which contained mitochon-
drially bound HK contained 6% of the total activity.
Preincubation of both the soluble and particulate
HK 9L cell fractions in medium containing from
25 µM up to 1.25 mM LND for 10 min resulted in no
detectable inhibition of HK in either sample frac-
tion. Thus, we find no support for the suggestion
that LND is a selective inhibitor of the mitochon-
drial form of hexokinase. In fact, we have been un-
able to demonstrate any inhibition at all, of either
soluble or mitochondrial form. Moreover, if LND
was an inhibitor of HK, it would be anticipated that
such inhibition would result in a net decrease in glu-
cose 6-phosphate formation with a subsequent de-
crease in basal activity of the PPP. This however was
not the case, as PPP activity remained at approxi-
mately 10% of glucose metabolized through the
PPP relative to glycolysis in the presence and ab-
sence of LND. It is also interesting to note that al-
though subcutaneous tumor pH tended to recover
during the 3 hr experimental time period, ATP/Pi
levels did not recover. This is possibly due to the
fact that inhibition of lactate transport by LND oc-
curred at the lactate transporter site in the cell
membrane resulting in a new, lower rate of glucose
to lactate production. However, pH regulatory
mechanisms remain intact thereby allowing the
cells to neutralize their pH over time.
Interestingly, the decrease in pHi was dependent
on extracellular pH with a much higher LND-in-
duced pHi shift observed at [pH]e of 6.6. This data
suggested that a possible mechanism of action of
LND involved inhibition of the pH-dependent [27]
lactate efflux across the plasma membrane. LND
exposure resulted in a 5-fold increase in intracellu-
lar lactate accumulation accompanied by a de-
creased in lactate release to about 20% of control
values. The lack of effects of LND on HK and PPP
activities, the exacerbated LND-induced reduction
in pHi under extracellular acidic conditions and the
LND-induced intracellular accumulation of lactate
suggest that the mechanism of LND action does not
involve HK inhibition but rather inhibition of lac-
tate efflux and intracellular acidification. This is al-
so in agreement with Ben-Horin et al. [20] who re-
ported a more than 3-fold increase in intracellular
lactate content in MCF-7 human breast cancer cells
exposed to LND using 13C MRS. Furthermore, in an
elegant 31P MRS study, these workers have also
shown that LND had no effect on the buildup of 2-
deoxyglucose 6-phosphate compared with 2-deox-
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yglucose alone. 2-Deoxyglucose is phosphorylated
by HK to form 2-deoxyglucose 6-phosphate, which
is not further metabolized thus inhibiting glycolysis.
Since treating the cells with a combination of 2-de-
oxyglucose and LND did not result in a reduction in
2-deoxyglucose 6-phosphate accumulation, these
authors concluded that LND did not act as a signif-
icant HK inhibitor in intact perfused tumor cells.
In conclusion, this study demonstrated a signif-
icant reduction in rat 9L gliosarcoma pHi and ATP
occurred in vivo following administration of LND
which is likely attributable to an inhibition of lac-
tate efflux rather than by a direct inhibition of HK.
Since lowering pHi has been shown to sensitize tu-
mor cells to various therapies such as hyperthermia
[28], the relative selectivity of LND for reducing 9L
tumor pHi and ATP levels should prove to be bene-
ficial. However, further work is needed to deter-
mine if the effects of LND on subcutaneous glioma
pH and ATP levels can be reproduced on intrace-
rebral gliomas. Providing that intracerebral studies
are positive, studies combining the use of LND and
radiation and/or hyperthermia would be warrant-
ed. Finally, the use of in vivo 31P NMR to dynamical-
ly follow the changes in tumor pH and ATP levels
should provide a valuable method for optimizing
both the dose of LND as well as the timing of sub-
sequent adjunctive therapy following LND admin-
istration.
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